All Stories

  1. Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells

    Article • The EMBO Journal, September 2025, Springer Science + Business Media

    Dr Simak Ali

  2. TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer

    Article • Proceedings of the National Academy of Sciences, August 2025, Proceedings of the National Academy of Sciences

    Dr Simak Ali

  3. Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (Pueraria lobata)

    Article • Journal of Natural Products, June 2025, American Chemical Society (ACS)

    Dr Simak Ali

  4. Abstract 11: Overexpression of midasin drives cancer stem cell dynamics in ESR1 mutant breast cancer

    Article • Cancer Research, April 2025, American Association for Cancer Research (AACR)

    Dr Simak Ali

  5. Abstract 6768: Targeting the Her2 and ERα receptors has a significant impact on therapy-resistant ER-positive breast cancer

    Article • Cancer Research, April 2025, American Association for Cancer Research (AACR)

    Dr Simak Ali

  6. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    Article • Nature Communications, March 2025, Springer Science + Business Media

    Dr Simak Ali

  7. Correction: Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes

    Article • PLOS One, December 2024, PLOS

    Dr Koralia Paschalaki, Dr Simak Ali

  8. Data from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  9. Supplementary Figures from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  10. Supplementary Table 3 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  11. Supplementary Table 4 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  12. Supplementary Table 5 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  13. Supplementary Table 6 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  14. Supplementary Table S1 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  15. Supplementary Table S2 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • December 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  16. Erratum: Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer

    Article • JCO Precision Oncology, December 2024, American Society of Clinical Oncology (ASCO)

    Dr Simak Ali

  17. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer

    Article • JCO Precision Oncology, December 2024, American Society of Clinical Oncology (ASCO)

    Dr Simak Ali

  18. Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma

    Article • The EMBO Journal, November 2024, Springer Science + Business Media

    Dr Simak Ali, Tim Fenton

  19. Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer

    Article • Cancer Research, October 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  20. Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer

    Article • Anti-Cancer Drugs, August 2024, Wolters Kluwer Health

    Dr Simak Ali

  21. Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2–Positive Disease

    Article • JCO Precision Oncology, June 2024, American Society of Clinical Oncology (ASCO)

    Dr Simak Ali

  22. Abstract PO2-24-04: Exploring the role and therapeutic potential of Ubiquitin Specific Peptidase 11 (USP11) in estrogen receptor positive breast cancer

    Article • Cancer Research, May 2024, American Association for Cancer Research (AACR)

    Dr Simak Ali

  23. Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice

    Article • Endocrinology, April 2024, Endocrine Society

    Dr Simak Ali

  24. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling

    Article • Scientific Reports, March 2024, Springer Science + Business Media

    Dr Simak Ali

  25. High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design

    Article • Nature Communications, March 2024, Springer Science + Business Media

    Dr Simak Ali

  26. Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma

    Article • March 2024, Springer Science + Business Media

    Dr Simak Ali, Tim Fenton

  27. Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

    Article • British Journal of Cancer, February 2024, Springer Science + Business Media

    Dr Simak Ali

  28. Selective inhibition of CDK9 in triple negative breast cancer

    Article • Oncogene, November 2023, Springer Science + Business Media

    Dr Simak Ali

  29. The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation

    Article • Cancers, November 2023, MDPI AG

    Dr Simak Ali

  30. Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition

    Article • Molecular Cell, November 2023, Elsevier

    Dr Janos KristonVizi, Dr Simak Ali

  31. Deciphering Mutational Signature Dynamics in Hormone-Sensitive Breast Cancer During Treatment Adaptation.

    Article • October 2023, Springer Science + Business Media

    Dr Simak Ali

  32. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    Article • Nature Communications, August 2023, Springer Science + Business Media

    Dr Simak Ali

  33. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    Article • Nature Communications, July 2023, Springer Science + Business Media

    Dr Simak Ali

  34. Distinguishing PIK3CA p.E545K Mutational Status from Pseudogene DNA with a Next-Generation ISFET Sensor Array

    Article • May 2023, Institute of Electrical & Electronics Engineers (IEEE)

    Dr Simak Ali

  35. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

    Article • British Journal of Cancer, April 2023, Springer Science + Business Media

    Dr Simak Ali

  36. The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo

    Article • Cancers, April 2023, MDPI AG

    Dr Simak Ali

  37. Abstract 1557: Defining modulators of response to samuraciclib, a CDK7 inhibitor for breast cancer

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  38. Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  39. Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  40. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  41. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  42. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  43. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  44. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  45. Supplementary Data from Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • March 2023, American Association for Cancer Research (AACR)

    Dr Simak Ali

  46. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer

    Article • Oncogene, October 2022, Springer Science + Business Media

    Dr Simak Ali

  47. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer

    Article • British Journal of Cancer, September 2022, Springer Science + Business Media

    Dr Simak Ali

  48. Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence

    Article • Nature Communications, August 2022, Springer Science + Business Media

    Dr Simak Ali

  49. Harnessing the power of cryo-EM for development of cancer therapeutics: high-resolution structures of the human CDK-activating kinase bound to inhibitors

    Article • Acta Crystallographica Section A Foundations and Advances, July 2022, International Union of Crystallography

    Dr Simak Ali

  50. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer

    Article • June 2022, Cold Spring Harbor Laboratory Press

    Dr Simak Ali

  51. A comparison between Mini-loop mediated isothermal amplification and polymerase spiral reaction for selective amplification of short template DNA

    Article • May 2022, Cold Spring Harbor Laboratory Press

    Dr Simak Ali

  52. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

    Article • Nature Communications, April 2022, Springer Science + Business Media

    Dr Simak Ali

  53. Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer

    Article • Oncogene, February 2022, Springer Science + Business Media

    Dr Simak Ali, Tim Fenton

  54. Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

    Article • Cancer Research, February 2022, American Association for Cancer Research (AACR)

    Dr Simak Ali

  55. Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

    Article • Cancer Research, February 2022, American Association for Cancer Research (AACR)

    Dr Simak Ali

  56. HotspotESR1Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Article • Cancer Research, January 2022, American Association for Cancer Research (AACR)

    Dr Simak Ali

  57. Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer

    Article • Cancers, December 2021, MDPI AG

    Dr Simak Ali

  58. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease

    Article • JCO Precision Oncology, November 2021, American Society of Clinical Oncology (ASCO)

    Dr Simak Ali

  59. MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells

    Article • Biochemical Pharmacology, October 2021, Elsevier

    Dr Simak Ali

  60. Detection of Multiple Breast Cancer ESR1 Mutations on an ISFET Based Lab-on-Chip Platform

    Article • IEEE Transactions on Biomedical Circuits and Systems, June 2021, Institute of Electrical & Electronics Engineers (IEEE)

    Dr Simak Ali

  61. BK polyomavirus (BKPyV) is a risk factor for bladder cancer through induction of APOBEC3-mediated genomic damage

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Dr Simak Ali

  62. HotspotESR1mutations are multimodal and contextual drivers of breast cancer metastasis

    Article • February 2021, Cold Spring Harbor Laboratory Press

    Dr Simak Ali

  63. 2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942

    Article • Biophysical Journal, February 2021, Elsevier

    Dr Simak Ali

  64. ESR1mutant breast cancers show elevated basal cytokeratins and immune activation

    Article • December 2020, Cold Spring Harbor Laboratory Press

    Dr Simak Ali

  65. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB

    Article • Oncogene, December 2020, Springer Science + Business Media

    Dr Simak Ali

  66. Developing themes in targeted therapies for hormone receptor–positive breast cancer

    Article • Current Opinion in Endocrine and Metabolic Research, December 2020, Elsevier

    Dr Simak Ali

  67. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer

    Article • Breast Cancer Research, November 2020, Springer Science + Business Media

    Dr Simak Ali

  68. Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments

    Article • eLife, September 2020, eLife

    Dr Simak Ali

  69. The transcriptional repressor REV-ERB as a novel target for disease

    Article • Bioorganic & Medicinal Chemistry Letters, September 2020, Elsevier

    Dr Simak Ali

  70. Preface

    Article • Cancer and Metastasis Reviews, August 2020, Springer Science + Business Media

    Executive Director, The Hormel Institute Robert Clarke, Dr Simak Ali

  71. 90 Years of progesterone: Ninety years of progesterone: the ‘other’ ovarian hormone

    Article • Journal of Molecular Endocrinology, July 2020, Bioscientifica

    Dr Simak Ali

  72. Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer

    Article • Cancer Research, May 2020, American Association for Cancer Research (AACR)

    Dr Simak Ali

  73. CDK7 inhibitors as anticancer drugs

    Article • Cancer and Metastasis Reviews, May 2020, Springer Science + Business Media

    Dr Simak Ali

  74. A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation

    Article • Scientific Reports, March 2020, Springer Science + Business Media

    Dr Simak Ali

  75. Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments

    Article • March 2020, Cold Spring Harbor Laboratory Press

    Dr Simak Ali

  76. Abstract P6-04-18: The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer

    Article • Cancer Research, February 2020, American Association for Cancer Research (AACR)

    Dr Simak Ali

  77. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer

    Article • British Journal of Cancer, September 2019, Springer Science + Business Media

    Dr Simak Ali

  78. ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942

    Article • Oncogene, September 2019, Springer Science + Business Media

    Dr Simak Ali

  79. Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

    Article • Nature Communications, August 2019, Springer Science + Business Media

    Dr Simak Ali

  80. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence

    Article • Clinical Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Dr Simak Ali

  81. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES

    Article • Breast Cancer Research and Treatment, January 2019, Springer Science + Business Media

    Dr Simak Ali

  82. Abstract 4834: CT7001: An orally bioavailable CDK7 inhibitor is a potential therapy for breast, small-cell lung and haematological cancers

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr Simak Ali

  83. Abstract LB-224: Circulating tumor DNA for early detection and intervention in breast cancer: ctDNA profiles discriminate between healthy women in a true cancer screening setting and disease-free women on follow up

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr Simak Ali

  84. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

    Article • Molecular Cancer Therapeutics, May 2018, American Association for Cancer Research (AACR)

    Dr Simak Ali

  85. Author Correction: The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation

    Article • Scientific Reports, March 2018, Nature

    Dr Simak Ali

  86. Light-triggered enzymatic reactions in nested vesicle reactors

    Article • Nature Communications, March 2018, Nature

    Dr Simak Ali

  87. Corrigendum: Inhibitor Selectivity for Cyclin‐Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study

    Article • ChemMedChem, January 2018, Wiley

    Dr Simak Ali

  88. Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer

    Article • Breast Cancer Research and Treatment, January 2018, Springer Science + Business Media

    Dr Simak Ali

  89. The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation

    Article • Scientific Reports, November 2017, Nature

    Dr Simak Ali

  90. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells

    Article • Nucleic Acids Research, August 2017, Oxford University Press (OUP)

    Dr Simak Ali, Tim Fenton

  91. Erratum: Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

    Article • Nature Genetics, June 2017, Springer Science + Business Media

    Dr Simak Ali

  92. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer

    Article • Breast Cancer Research and Treatment, March 2017, Springer Science + Business Media

    Dr Simak Ali

  93. Heterodimers of photoreceptor-specific nuclear receptor (PNR/NR2E3) and peroxisome proliferator-activated receptor-γ (PPARγ) are disrupted by retinal disease-associated mutations

    Article • Cell Death and Disease, March 2017, Springer Science + Business Media

    Dr Simak Ali

  94. Inhibitor Selectivity for Cyclin‐Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study

    Article • ChemMedChem, February 2017, Wiley

    Dr Simak Ali

  95. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

    Article • Nature Genetics, January 2017, Springer Science + Business Media

    Dr Simak Ali

  96. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts

    Article • Clinical Cancer Research, January 2017, American Association for Cancer Research (AACR)

    Dr Simak Ali

  97. Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer

    Article • Clinical Cancer Research, November 2016, American Association for Cancer Research (AACR)

    Dr Simak Ali

  98. Have you cleaned your stethoscope today?

    Article • Journal of Hospital Infection, November 2016, Elsevier

    Dr Simak Ali

  99. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer

    Article • Oncogene, October 2016, Springer Science + Business Media

    Dr Simak Ali

  100. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis

    Article • Breast Cancer Research and Treatment, August 2016, Springer Science + Business Media

    Dr Simak Ali

  101. UK Breast Cancer Research Symposium 2016: Submitted Abstracts

    Article • Breast Cancer Research and Treatment, August 2016, Springer Science + Business Media

    Dr Simak Ali

  102. Abstract LB-339: Mutation analysis of cell-free DNA captures heterogeneity of individual circulating tumor cells in metastatic breast cancer

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr Simak Ali

  103. Clinicopathologic significance of androgen receptor expression in invasive breast cancer: A comprehensive analysis in large cohorts

    Article • European Journal of Cancer, July 2016, Elsevier

    Dr Simak Ali

  104. Abstract P5-08-17: A study of c-Jun N-terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer

    Article • Cancer Research, February 2016, American Association for Cancer Research (AACR)

    Dr Simak Ali

  105. Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes

    Article • PLOS One, February 2016, PLOS

    Dr Koralia Paschalaki, Dr Simak Ali

  106. SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer

    Article • Clinical Cancer Research, January 2016, American Association for Cancer Research (AACR)

    Dr Simak Ali

  107. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

    Article • Nature Communications, November 2015, Springer Science + Business Media

    Dr Simak Ali

  108. Oestrogen receptors and epigenetics in breast cancer aetiology and outcome

    Article • Endocrine Abstracts, October 2015, Bioscientifica

    Dr Simak Ali

  109. APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer

    Article • Cell Reports, October 2015, Elsevier

    Dr Simak Ali

  110. LRH-1 drives colon cancer cell growth by repressing the expression of theCDKN1Agene in a p53-dependent manner

    Article • Nucleic Acids Research, September 2015, Oxford University Press (OUP)

    Dr Simak Ali

  111. Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer

    Article • Clinical Chemistry, May 2015, AACC

    Dr Simak Ali, JIn Luo, David Guttery

  112. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer

    Article • Oncotarget, May 2015, Impact Journals, LLC

    Dr Simak Ali

  113. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer

    Article • Breast Cancer Research and Treatment, March 2015, Springer Science + Business Media

    Dr Simak Ali

  114. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer

    Article • Breast Cancer Research and Treatment, March 2015, Springer Science + Business Media

    Dr Simak Ali

  115. Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

    Article • Breast Cancer Research and Treatment, August 2014, Springer Science + Business Media

    Dr Greg N Brooke, Dr Simak Ali

  116. The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin β 1

    Article • Science Signaling, June 2014, American Association for the Advancement of Science

    Dr Simak Ali

  117. Engineered repressors are potent inhibitors of androgen receptor activity

    Article • Oncotarget, March 2014, Impact Journals, LLC

    Dr Simak Ali

  118. Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance

    Article • British Journal of Cancer, September 2013, Springer Science + Business Media

    Dr Simak Ali

  119. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells

    Article • Nucleic Acids Research, September 2013, Oxford University Press (OUP)

    Dr Simak Ali

  120. Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells

    Article • August 2013, Bioscientifica

    Dr Greg N Brooke, Dr Simak Ali

  121. Abstract 4762: Anti-Nicastrin antibodies for the treatment of endocrine resistant breast cancer .

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Dr Simak Ali

  122. A Common Deletion in the APOBEC3 Genes and Breast Cancer Risk

    Article • JNCI Journal of the National Cancer Institute, February 2013, Oxford University Press (OUP)

    Dr Simak Ali

  123. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

    Article • Breast Cancer Research, January 2013, Springer Science + Business Media

    Professor Martin O Leach, Dr Simak Ali

  124. Abstract P2-10-22: Phosphorylation of Steroid Receptor Coactivator 3 (SRC3) at Ser543 is a novel independent prognostic marker in breast cancer

    Article • Cancer Research, December 2012, American Association for Cancer Research (AACR)

    Dr Simak Ali

  125. Discovery of a New Class of Liver Receptor Homolog-1 (LRH-1) Antagonists: Virtual Screening, Synthesis and Biological Evaluation

    Article • ChemMedChem, September 2012, Wiley

    Eric Anthony Ortlund, Dr Simak Ali

  126. Development of a Novel Molecular Sensor for Imaging Estrogen Receptor-Coactivator Protein-Protein Interactions

    Article • PLOS One, August 2012, PLOS

    Dr Simak Ali

  127. Abstract 4205: Identification of glycine N-methyltransferase-regulated genes in prostate cancer cells

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Simak Ali

  128. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

    Article • Nature, January 2012, Springer Science + Business Media

    Dr Simak Ali

  129. Conversion of α-Amino Acids into Bioactive o-Aminoalkyl Resorcylates and Related Dihydroxyisoindolinones

    Article • The Journal of Organic Chemistry, June 2011, American Chemical Society (ACS)

    Dr Simak Ali

  130. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer

    Article • Nature Reports Stem Cells, May 2011, Springer Science + Business Media

    Dr Simak Ali

  131. Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other Diseases

    Article • Annual Review of Medicine, February 2011, Annual Reviews

    Dr Simak Ali

  132. A Novel Pyrazolo[1,5-a]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration

    Article • Journal of Medicinal Chemistry, November 2010, American Chemical Society (ACS)

    Dr Simak Ali

  133. Concise, flexible syntheses of 4-(4-imidazolyl)pyrimidine cyclin-dependent kinase 2 (CDK2) inhibitors

    Article • Tetrahedron Letters, November 2010, Elsevier

    Dr Simak Ali

  134. A simple laboratory practical to illustrate RNA mediated gene interference using drosophila cell culture

    Article • Biochemistry and Molecular Biology Education, November 2010, Wiley

    Dr Simak Ali

  135. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth

    Article • Breast Cancer Research and Treatment, August 2010, Springer Science + Business Media

    Dr Simak Ali

  136. The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells

    Article • Breast Cancer Research and Treatment, July 2010, Springer Science + Business Media

    Mr William H Hudson, Eric Anthony Ortlund, Dr Simak Ali

  137. Abstract LB-178: Characterization of estrogen responses in breast cancer cell lines highlights ERα as an LRH-1 regulated gene

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr Simak Ali

  138. The DEAD-box protein p72 regulates ERα-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERα-positive breast cancer

    Article • Oncogene, August 2009, Springer Science + Business Media

    Dr Simak Ali

  139. The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity

    Article • Cancer Research, July 2009, American Association for Cancer Research (AACR)

    Dr Simak Ali

  140. Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells

    Article • Oncogene, April 2009, Springer Science + Business Media

    Dr Simak Ali

  141. Erratum: Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen

    Article • Nature, February 2009, Springer Science + Business Media

    Dr Simak Ali

  142. Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen

    Article • Nature, December 2008, Springer Science + Business Media

    Dr Simak Ali

  143. The DEAD box RNA helicases p68 (Ddx5) and p72 (Ddx17): novel transcriptional co-regulators

    Article • Biochemical Society Transactions, July 2008, Portland Press Ltd.

    Dr Simak Ali

  144. Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity

    Article • Journal of Molecular Endocrinology, February 2008, Bioscientifica

    Dr Simak Ali

  145. Phosphorylation of Estrogen Receptor-α at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients

    Article • Clinical Cancer Research, October 2007, American Association for Cancer Research (AACR)

    Dr Simak Ali

  146. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases

    Article • Nucleic Acids Research, November 2006, Oxford University Press (OUP)

    Dr Simak Ali

  147. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

    Article • Endocrine Related Cancer, September 2006, Bioscientifica

    Dr Simak Ali

  148. T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif

    Article • Nucleic Acids Research, October 2005, Oxford University Press (OUP)

    Dr Simak Ali

  149. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation

    Article • Endocrine Related Cancer, July 2005, Bioscientifica

    Dr Simak Ali

  150. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

    Article • The Lancet Oncology, June 2005, Elsevier

    Dr Simak Ali

  151. Erratum: Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF

    Article • Gene Therapy, May 2005, Springer Science + Business Media

    Dr Simak Ali

  152. Erratum: Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF

    Article • Gene Therapy, March 2005, Springer Science + Business Media

    Dr Simak Ali

  153. ICI182,780 Induces p21 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line

    Article • Journal of Biological Chemistry, February 2005, Elsevier

    Dr Simak Ali

  154. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF

    Article • Gene Therapy, January 2005, Springer Science + Business Media

    Dr Simak Ali

  155. Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines

    Article • Clinical Cancer Research, December 2004, American Association for Cancer Research (AACR)

    Dr Simak Ali

  156. Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor

    Article • Oncogene, August 2004, Springer Science + Business Media

    Dr Simak Ali

  157. The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity

    Article • Carcinogenesis, June 2004, Oxford University Press (OUP)

    Dr Simak Ali

  158. Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

    Article • JNCI Journal of the National Cancer Institute, June 2004, Oxford University Press (OUP)

    Dr Simak Ali

  159. Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function

    Article • British Journal of Cancer, February 2004, Springer Science + Business Media

    Dr Simak Ali

  160. The Nuclear Oxysterol Receptor LXRα Is Expressed in the Normal Human Breast and in Breast Cancer

    Article • Medical Oncology, January 2004, Springer Science + Business Media

    Dr Simak Ali

  161. T:G Mismatch-specific Thymine-DNA Glycosylase Potentiates Transcription of Estrogen-regulated Genes through Direct Interaction with Estrogen Receptor α

    Article • Journal of Biological Chemistry, October 2003, Elsevier

    Dr Simak Ali

  162. Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: A pilot study

    Article • International Journal of Cancer, September 2003, Wiley

    Dr Simak Ali

  163. Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation

    Article • Journal of Biological Chemistry, August 2003, Elsevier

    Dr Simak Ali

  164. Investigation of Estrogen Receptor Phosphorylation Using Phosphospecific Antibodies

    Article • Clinical Science, April 2003, Portland Press Ltd.

    Dr Simak Ali

  165. Purified malignant mammary epithelial cells maintain hormone responsiveness in culture

    Article • British Journal of Cancer, April 2003, Springer Science + Business Media

    Dr Simak Ali

  166. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation

    Article • The Journal of Steroid Biochemistry and Molecular Biology, August 2002, Elsevier

    Dr Simak Ali

  167. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

    Article • Oncogene, July 2002, Springer Science + Business Media

    Dr Simak Ali

  168. Endocrine-responsive breast cancer and strategies for combating resistance

    Article • Nature Reviews Drug Discovery, February 2002, Springer Science + Business Media

    Dr Simak Ali

  169. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

    Article • Journal of Biological Chemistry, March 2001, Elsevier

    Dr Simak Ali

  170. Analysis of estrogen‐responsive finger protein expression in benign and malignant human breast

    Article • International Journal of Cancer, January 2001, Wiley

    Dr Simak Ali

  171. Retroviral infection of the FGF2 gene into MCF-7 cells induces branching morphogenesis, retards cell growth and suppresses tumorigenicity in nude mice

    Article • European Journal of Cancer, January 2001, Elsevier

    Dr Simak Ali

  172. Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance

    Article • Journal of Mammary Gland Biology and Neoplasia, July 2000, Springer Science + Business Media

    Dr Simak Ali

  173. Activation of Estrogen Receptor ? by S118 Phosphorylation Involves a Ligand-Dependent Interaction with TFIIH and Participation of CDK7

    Article • Molecular Cell, July 2000, Elsevier

    Dr Simak Ali

  174. Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization

    Article • Molecular and Cellular Biology, February 1999, ASM Journals

    Dr Simak Ali

  175. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata

    Article • Genes Chromosomes and Cancer, December 1998, Wiley

    Dr Simak Ali

  176. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers

    Article • International Journal of Cancer, August 1998, Wiley

    Dr Simak Ali

  177. Human Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor α

    Article • Journal of Biological Chemistry, October 1997, Elsevier

    Dr Simak Ali

  178. Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance

    Article • British Journal of Cancer, April 1997, Springer Science + Business Media

    Dr Simak Ali

  179. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo

    Article • Molecular Endocrinology, May 1995, Endocrine Society

    Dr Simak Ali

  180. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo.

    Article • Molecular Endocrinology, May 1995, Endocrine Society

    Dr Simak Ali

  181. Characterization of the Amino-terminal Transcriptional Activation Function of the Human Estrogen Receptor in Animal and Yeast Cells

    Article • Journal of Biological Chemistry, April 1995, Elsevier

    Dr Simak Ali

  182. Production and Characterization of Monoclonal Antibodies Recognising Defined Regions of the Human Oestrogen Receptor

    Article • Hybridoma, August 1993, Mary Ann Liebert Inc

    Dr Simak Ali

  183. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region.

    Article • The EMBO Journal, March 1993, Springer Science + Business Media

    Dr Simak Ali

  184. Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL-VP16 and the two nonacidic activation functions of the estrogen receptor

    Article • Nucleic Acids Research, January 1993, Oxford University Press (OUP)

    Laszlo Tora, Dr Simak Ali

  185. Retinoic acid receptor-beta: immunodetection and phosphorylation on tyrosine residues

    Article • Molecular Endocrinology, December 1992, Endocrine Society

    Dr Simak Ali

  186. Immunodetection of multiple species of retinoic acid receptor α: Evidence for phosphorylation

    Article • Experimental Cell Research, August 1992, Elsevier

    Dr Simak Ali

  187. Developmental regulation of the sheep β‐lactoglobulin gene in the mammary gland of transgenic mice

    Article • Developmental Genetics, January 1991, Wiley

    Dr Simak Ali

  188. Characterisation of the alleles encoding ovine ß-lactoglobulins A and B

    Article • Gene, July 1990, Elsevier

    Dr Simak Ali

  189. Gene expression in the mammary gland

    Article • Reproduction, March 1990, Bioscientifica

    Dr Simak Ali

  190. The molecular manipulation of milk composition

    Article • Genome, January 1989, Canadian Science Publishing

    Dr Simak Ali

  191. Characterization of the gene encoding ovine beta-lactoglobulin

    Article • Journal of Molecular Biology, February 1988, Elsevier

    Dr Simak Ali

  192. Complete nucleotide sequence of the genomic ovine β-lactoglobulin gene

    Article • Nucleic Acids Research, January 1988, Oxford University Press (OUP)

    Dr Simak Ali

  193. Estrogen Receptors and Anti-Estrogen Therapies

    Article • Springer Science + Business Media

    Dr Simak Ali

  194. Transcriptional Coactivators and Corepressors in Endocrine Response and Resistance in Breast Cancer

    Article • Springer Science + Business Media

    Dr Simak Ali